intern
symposium
hiv
emerg
infecti
diseas
isheid
held
marseil
franc
may
meet
attract
deleg
world
outsid
franc
allow
interact
discuss
around
hiv
viral
hepat
new
influenza
strain
merscov
chikungunya
infect
articl
focu
aspect
discuss
point
view
hiv
infect
emphasi
much
antiretrovir
therapi
new
compound
develop
result
recent
phase
iii
trial
well
treatment
issu
young
adolesc
less
young
age
epidem
becom
chronic
diseas
end
epidem
develop
prophylact
vaccin
hiv
erad
took
front
stage
sever
occas
three
day
confer
start
thirti
year
discoveri
hiv
ten
big
mistak
stefano
vella
remind
us
hope
earli
day
epidem
prophylact
vaccin
within
next
year
predict
probabl
refer
margaret
heckler
declar
said
abl
grow
hiv
would
help
find
vaccin
one
day
vella
also
list
shortlif
experi
treatment
interrupt
contrari
prolong
use
delay
use
surrog
marker
understand
artassoci
sideeffect
lipodystrophi
also
took
time
take
account
impact
art
prevent
measur
exact
time
art
initi
still
assess
ongo
studi
stefano
vella
conclud
understand
hiv
pathogenesi
develop
new
drug
pave
way
dramat
progress
term
morbid
mortal
combin
therapi
nearli
million
individu
treatment
worldwid
appal
discrep
access
rich
develop
countri
progress
fill
process
also
exemplifi
guidelin
treatment
adult
align
intern
committe
mark
wainberg
spoke
futur
challeng
strong
emphasi
find
cure
hiv
infect
current
effort
provid
arv
million
peopl
infect
hiv
develop
countri
may
sustain
professor
wainberg
hypothes
dolutegravir
qualit
superior
drug
predecessor
drug
resist
dolutegravir
may
imposs
compound
use
first
line
therapi
reason
effici
drug
bind
integras
enzym
greatli
reduc
viral
fit
virus
becom
minim
resist
state
patient
dolutegravir
may
unabl
transmit
hiv
use
drug
may
therefor
contribut
end
hiv
epidem
session
manag
antiretrovir
therapi
remind
us
robust
pipelin
new
compound
develop
roy
gulick
discuss
need
new
nrti
activ
resist
viral
strain
less
longterm
toxic
tenofovir
alafenamid
fumar
known
taf
develop
show
viremia
decreas
log
day
dose
display
safer
toxic
profil
term
kidney
bone
tenofovir
doravirin
potent
new
nnrti
metabol
activ
vitro
viral
strain
develop
attach
inhibitor
class
interest
one
daili
compound
activ
cenicriviroc
also
potenti
antiinflammatori
properti
attach
inhibitor
new
mechan
action
bind
envelop
protein
therefor
differ
form
class
drug
activ
hiv
strain
potent
well
toler
import
result
latt
studi
show
rilpivirn
gsk
oral
mainten
therapi
suppress
viremia
pave
way
test
inject
form
combin
might
deliver
monthli
basi
use
preexposur
prophylaxi
agent
also
test
soon
excit
develop
inject
longact
arv
present
marta
boffito
term
first
line
therapi
marc
nelson
present
posit
result
recent
trial
newli
develop
antiretrovir
drug
phase
iii
elvitegravir
dolutegravir
stress
favour
resist
profil
dolutegravir
togeth
remind
us
mechan
action
tubular
level
booster
cobicistat
delay
occur
detect
mani
artassoci
toxic
drug
cost
forefront
treatment
agenda
gener
formul
mani
antiretrovir
avail
way
import
impact
drug
cost
futur
trial
first
line
therapi
lopinavirritonavir
lpvr
vs
nevirapin
nnrti
develop
countri
random
trial
nathan
clumeck
show
favour
outcom
protein
inhibitorbas
regimen
discuss
switch
strategi
daniel
podzam
review
caus
switch
art
within
context
imperfect
art
adher
problem
toxic
among
other
remind
us
switch
strategi
test
import
issu
clinician
encount
nowaday
hiv
chronic
diseas
character
process
associ
increas
morbid
morbid
relat
tradit
aidsdefin
event
cardiovascular
renal
metabol
bone
diseas
chronic
inflamm
discuss
frank
miedema
one
critic
factor
hiv
pathogenesi
like
caus
nonaid
endorgan
diseas
encount
chronic
hiv
infect
atherosclerosi
cardiovascular
diseas
kidney
failur
neuropatholog
process
remain
activ
even
combin
art
age
hiv
paddi
mallon
review
variou
marker
immun
dysfunct
chang
associ
age
hiv
infect
age
process
hiv
infect
associ
similar
chang
besid
immun
dysfunct
bone
chang
cardiovascular
diseas
ration
conclus
regard
comorbid
hivpati
address
earli
long
view
regard
choic
art
regimen
take
consider
factor
accord
barri
peter
place
statin
review
kenneth
lichtenstein
conclus
term
risk
type
diabet
benefit
outweigh
risk
lipid
level
also
whole
stori
stress
import
lifestyl
chang
weight
reduct
smoke
cessat
side
age
spectrum
deal
young
popul
either
infect
vertic
horizont
due
improv
treatment
children
born
hiv
reach
adulthood
rana
chakraborthi
reiter
import
organ
transit
process
hiv
infect
youth
adult
healthcar
system
use
multidisciplinari
individu
approach
differ
need
regard
particular
stigma
mental
health
high
rate
teen
pregnanc
two
popul
term
support
last
least
stop
epidem
achiev
cure
comprehens
review
provid
virgini
supervi
francoi
dabi
well
myron
cohen
need
track
current
state
epidem
earli
diagnosi
hiv
infect
prevent
acquisit
transmiss
hiv
prevent
tool
grown
past
year
acknowledg
impact
art
tool
prevent
myron
cohen
discuss
differ
prevent
strategi
intervent
uninfect
infect
individu
factor
associ
amplifi
transmiss
includ
associ
infecti
blood
genit
tract
viral
load
sexual
transmit
diseas
std
viral
clade
acut
infect
suscept
acquisit
viru
std
among
other
joep
lang
reiter
strong
argument
favor
earli
therapi
individu
public
health
benefit
implement
tasp
francoi
dabi
recommend
end
epidem
within
next
year
go
commun
counsel
test
treat
everybodi
promot
condom
use
male
circumcis
harm
reduct
possibl
cure
hiv
updat
reservoir
lian
show
complex
integr
particular
memori
precursor
cell
potenti
role
ctl
boost
elimin
infect
cell
pharmacolog
approach
ole
schmeltz
sogaard
cover
multipl
immmunologci
intervent
includ
neutralis
antibodi
besid
therapeut
hiv
vaccin
ab
nk
cell
peg
infalpha
tlr
agonist
other
gene
therapi
bone
marrow
transplant
discuss
joachim
hauber
jan
van
lutzen
gene
therapi
limit
low
number
transduc
cell
genotox
zinc
finger
nucleas
zfn
technolog
disadvantag
possibl
offtarget
effect
chromosom
instabl
joachim
hauber
present
next
gener
ltrspecif
trerecombinas
target
major
isol
attack
reservoir
directli
present
expand
subtyp
ann
gatignol
discuss
new
therapeut
target
gag
rna
access
ribozym
rna
interfer
molecul
particular
hepat
deltaderiv
ribozym
target
rna
longterm
inhibitori
activ
suggest
type
molecul
might
use
combin
gene
therapi
drug
develop
hiv
aid
vaccin
long
difficult
endeavor
far
met
mani
failur
hope
challeng
hiv
vaccin
research
discuss
isheid
confer
vaccin
challeng
includ
genet
divers
mutabl
creat
plethora
constantli
chang
antigen
structur
featur
viral
envelop
glycoprotein
disguis
conserv
receptorbind
site
immun
system
presenc
carbohydr
moieti
shield
potenti
epitop
antibodi
inde
contain
number
featur
help
viru
evad
host
humor
immun
includ
variabl
loop
nlink
glycosyl
conform
flexibl
disguis
conserv
receptorbind
site
humor
immun
system
presenc
carbohydr
moieti
shield
potenti
epitop
bind
antibodi
shown
czernekova
et
al
partial
remov
nglycan
increas
reactiv
panel
broadli
neutral
antibodi
sera
person
success
develop
hiv
vaccin
one
ten
big
challeng
highlight
marc
wainberg
also
point
limit
rate
success
develop
vaccin
form
sexual
transmit
diseas
obviou
except
human
papilloma
viru
review
marc
girard
first
efficaci
trial
hiv
vaccin
attempt
elicit
protect
antibodi
viral
envelop
prevent
infect
impact
level
viraemia
infect
next
set
antigen
use
clinic
efficaci
studi
design
test
whether
cell
could
protect
infect
neither
step
trial
gagpolnef
hvtn
trial
gagpolnefenv
primeboost
regimen
could
protect
infect
reduc
earli
plasma
level
proof
concept
possibl
vaccin
elicit
protect
immun
block
infect
came
clinic
trial
thailand
yield
reduct
acquisit
use
primeboost
vaccin
regimen
moreov
highlight
marc
girard
new
surrog
marker
protect
came
trial
includ
presenc
target
igg
loop
contain
bind
site
receptor
cell
involv
cell
migrat
galt
also
part
sever
neutral
epitop
includ
recogn
broad
neutral
antibodi
bnab
apex
spike
trial
also
show
strong
correl
protect
igg
target
domain
promot
adcc
sever
studi
address
question
correl
protect
infect
diseas
report
isheid
confer
resist
infect
among
expos
seroneg
partner
hivdiscord
coupl
associ
higher
frequenc
cell
express
ifn
ascompar
unexpos
subject
suggest
protect
role
hivspecif
ctl
protect
role
ctl
also
suggest
find
hiv
control
exhibit
high
frequenc
tcell
display
phenotyp
exert
exvivo
cytotox
activ
frequenc
cell
correl
capac
cell
inhibit
viral
replic
novel
experiment
approach
present
analyz
lymphocyt
post
treatment
control
ptc
particular
presenc
replic
compet
hiv
follow
transplant
raghu
mice
cell
ptc
subsequ
engraft
human
cell
broadli
reactiv
neutral
antibodi
bnab
found
select
individu
live
hiv
demonstr
human
capabl
make
broadli
neutral
antibodi
show
potent
crossclad
neutral
activ
strain
remark
protect
iv
mucos
hiv
shiv
infect
anim
model
suppress
activ
infect
mice
macaqu
bnab
develop
period
year
year
averag
infect
person
result
long
affin
matur
b
cell
extens
mutat
b
cell
lineag
seem
driven
long
antigen
exposur
vaccin
offer
protect
major
hiv
strain
henc
number
question
address
abl
design
vaccin
induc
rapid
product
protect
ab
ii
transfer
knowledg
crossspecif
antigen
immunogen
induc
power
protect
respons
follow
vaccin
iii
know
enough
b
cell
matur
plasmocyt
differenti
iv
immunogen
develop
consid
broadli
neutral
ab
identifi
hypermut
may
need
stimul
success
antibodi
recogn
epitop
neutral
seri
vaccin
v
induc
correct
b
cell
stimul
produc
ab
high
degre
affin
matur
vi
induc
humor
memori
mediat
longliv
antibodysecret
cell
vii
success
vaccin
smallpox
hepat
yf
elicit
broad
integr
respons
involv
effector
includ
innat
tlr
nk
respons
consid
innat
immun
influenc
qualit
quantit
featur
adapt
immun
identifi
innat
correl
protect
question
still
aris
whether
vaccin
prevent
infect
reduc
hiv
level
preserv
uninfect
memori
cell
would
benefit
recipi
sever
studi
present
isheid
confer
report
develop
new
therapeut
vaccin
candid
safeti
preclin
clinic
trial
new
technolog
report
confer
onestep
vivo
product
target
cell
effici
safe
dnaviruslik
particl
vlp
express
bce
lead
present
immunodomin
hiv
antigen
preclin
studi
genepro
lentivir
therapeut
vaccin
includ
hiv
gene
abl
induc
singl
high
dose
longlast
polyfunct
tcell
respons
nonhuman
primat
model
anoth
lentiviralbas
therapeut
vaccin
present
gener
strong
specif
longlast
tcell
respons
mice
current
evalu
haarttreat
patient
phase
iii
vaccin
trial
differ
approach
consist
induct
neutral
antibodi
matrix
protein
interact
epitop
specif
receptor
act
extracellularli
viral
toxin
peptidebas
immunogen
use
phase
trial
shown
gener
antibodi
abl
neutral
bind
cell
receptor
haarttreat
patient
still
detect
two
year
first
inject
final
novel
approach
protect
antibodi
infecti
diseas
recent
develop
vectorimmunoprophylaxi
vip
vectormedi
ab
gene
transfer
aim
elicit
passiv
immun
use
aav
vector
express
h
l
chain
monoclon
bnab
genetherapi
approach
success
test
anim
model
blt
mice
confer
full
protect
mucos
hiv
transmiss
suggest
suffici
high
circul
concentr
bnab
might
substanti
reduc
probabl
sexual
transmiss
hiv
human
search
hiv
vaccin
long
stori
start
earli
first
clinic
trial
perform
human
daniel
zaguri
long
road
still
ahead
promiz
strategi
howev
pipelin
hepat
c
viru
hcv
major
caus
chronic
liver
diseas
estim
million
peopl
infect
worldwid
hcv
identifi
envelop
viru
kb
singlestrand
rna
genom
member
flavivirida
famili
genu
hepaciviru
develop
new
molecul
call
direct
act
antivir
daa
lead
complet
chang
pictur
cure
diseas
hope
erad
overal
futur
bright
patient
chronic
infect
hcv
challeng
hcv
diseas
differ
peopl
regard
locat
hcv
infect
major
challeng
western
world
identifi
patient
hcv
associ
liver
diseas
would
benefit
therapi
far
minor
hcvinfect
individu
diagnos
portion
receiv
therapi
develop
world
challeng
differ
make
hcv
therapi
econom
afford
area
world
becom
major
challeng
hcv
lifecycl
begin
virion
attach
specif
receptor
hcv
rna
genom
serv
templat
viral
replic
viral
messeng
rna
viral
product
translat
polyprotein
cleav
proteas
viral
assembl
occur
potenti
step
viral
cycl
target
drug
develop
knowledg
structur
hcv
proteas
hcv
polymeras
allow
structurebas
drug
design
develop
inhibitor
enzym
sever
find
suggest
hcv
modul
ifn
induct
signal
attenu
express
ifn
stimul
gene
allow
hcv
escap
antivir
action
host
respons
hcv
enzym
proteas
helicas
rdrp
essenti
hcv
replic
potenti
drug
discoveri
target
therefor
daa
differ
viral
target
includ
proteas
inhibitor
nucleosidenucleotid
analogu
nonnucleosid
inhibitor
rnadepend
rna
polymeras
inhibitor
develop
rockstroh
describ
progress
made
hcv
diseas
emphasi
drug
combat
hcv
theoret
consid
curabl
sinc
hcv
integr
cell
howev
professor
rockstroh
highlight
hcv
therapi
yet
employ
suffici
extent
among
individu
enrol
control
clinic
trial
clearli
possibl
issu
nonadher
may
compromis
success
antihcv
drug
turn
could
lead
hcv
drug
resist
work
necessari
topic
lectur
new
anti
hcv
agent
fabien
zoulim
made
clear
pharmaceut
compani
still
activ
area
professor
vicent
soriano
spoke
treatment
coinfect
hcvhiv
patient
express
hope
sofosbuvir
sof
would
repres
huge
improv
abil
treat
hcv
professor
marc
bourlier
spoke
new
antihcv
drug
would
limit
use
much
toxic
interferon
ifn
ribivirin
rbv
approach
domin
field
decad
key
factor
decid
treat
patient
wait
patient
factor
includ
urgenc
treat
likelihood
respons
hcv
genotyp
treatment
experi
genotyp
degre
fibrosi
patient
motiv
treatment
factor
includ
efficaci
current
option
safeti
current
option
durat
therapi
pill
burden
dose
frequenc
futur
option
timelin
access
costsimpl
well
complex
strategi
develop
regard
avail
new
daa
toler
ifn
figur
genotyp
patient
combin
ifn
sof
balanc
ifnfre
regimen
base
nucleosid
inhibitor
ni
rbv
ni
proteas
inhibitor
pi
rbv
combin
ifn
pi
also
balanc
ifnfre
regimen
pi
rbv
pi
non
nucleosid
inhibitor
nni
rbv
pi
nni
rbv
genotyp
patient
combin
sof
rbv
week
treatment
lead
svr
next
standardofcar
genotyp
patient
combin
sof
rbv
week
lead
svr
daa
combin
current
studi
genotyp
patient
combin
sof
rbv
lead
respons
patient
week
therapi
week
combin
abbvi
drug
rbv
lead
svr
experienc
patient
treatment
experienc
noncirrhot
patient
combin
sof
rbv
week
lead
svr
cirrhot
patient
combin
ifn
rbv
sof
week
lead
svr
accord
harri
dalton
hepat
e
must
consid
common
emerg
diseas
develop
countri
caus
genotyp
mainli
affect
middleageselderli
male
zoonot
porcin
primari
host
howev
rout
transmiss
fulli
understood
evid
associ
pig
case
blood
transfus
must
consid
accordingli
high
number
asymptomat
viraem
donor
evid
hev
may
caus
persist
diseas
immunecompromis
solid
organ
transplant
recipi
individu
hiv
patient
haematolog
malign
patient
chronic
hev
infect
symptom
develop
rapidli
progress
liver
cirrhosi
hev
import
extrahepat
manifest
deserv
investig
exampl
dalton
et
al
shown
hev
neuropathogen
caus
wide
rang
neurolog
ill
expos
bruno
lina
human
usual
infect
avian
influenza
virus
aquat
wild
bird
howev
sporad
case
avian
influenza
viru
infect
observ
everi
year
mostli
asia
subsequ
adapt
emerg
virus
may
result
human
pandem
strain
recent
novel
influenza
viru
subtyp
isol
sever
diseas
patient
pneumonia
acut
respiratori
distress
syndrom
appar
healthi
poultri
march
eastern
china
viru
result
tripl
reassort
event
occur
wild
bird
transmiss
human
occur
wet
market
mostli
larg
citi
like
shanghai
adult
elderli
peopl
provision
fatal
rate
high
human
human
transmiss
report
far
explain
virolog
featur
strain
harbour
known
marker
requir
facilit
transmiss
mammal
expert
consid
viru
immin
threat
ten
year
sarscov
epidem
asia
newli
emerg
middl
east
lower
respiratori
tract
syndrom
merscov
confirm
patient
fatal
outcom
marcel
report
mer
case
link
arabian
peninsula
case
import
european
union
africa
bat
harbor
high
divers
relat
virus
suspect
anim
reservoir
recent
studi
reveal
dromedari
camel
like
intermedi
host
merscov
circul
dromedari
camel
decad
rais
question
whether
earlier
human
case
may
remain
undetect
preliminari
serolog
survey
saudi
arabia
could
determin
increas
seropreval
merscov
antibodi
popul
invitro
studi
show
merscov
inhibit
import
cellular
pathway
particular
inf
respons
confirmatori
invivo
experi
still
limit
due
lack
suitabl
anim
model
even
nonhuman
primat
combin
pegyl
ifnalpha
rbv
improv
clinic
symptom
confirm
previou
invitro
experi
develop
vaccin
ongo
vaccin
program
dromedari
camel
might
optim
choic
control
current
outbreak
prevent
futur
reintroduct
human
popul
major
chikungunya
outbreak
la
reunion
island
indian
ocean
mani
french
militari
policemen
deploy
french
militari
health
servic
armi
center
epidemiolog
public
health
could
follow
policemen
year
outbreak
also
studi
clinic
spectrum
treatment
rheumat
complic
chikungunya
infect
patient
la
reunion
island
period
militari
policemen
deploy
reunion
island
chikungunya
outbreak
enquir
selfdeclar
chikungunya
infect
chik
posit
serolog
selfquestionnair
sent
person
respond
chik
latter
present
higher
frequenc
rheumat
disord
significantli
lower
qualiti
life
qol
noninfect
chik
respond
month
outbreak
six
year
later
particip
enquiri
sent
selfquestionnair
postmail
inform
consent
present
studi
propos
new
biolog
test
could
reach
fulfil
questionnair
chik
chik
result
base
declar
chik
patient
declar
higher
health
care
consumpt
complain
frequent
intens
joint
pain
versu
least
week
versu
moder
intens
pain
stiff
swell
frequent
fatigu
headach
depress
mood
respect
versu
p
dimens
qol
significantli
impair
chik
patient
reflect
social
physic
mental
impact
diseas
larg
differ
observ
rheumat
morbid
fatigu
qol
lead
conclus
chik
infect
long
term
impact
health
social
life
qol
low
proport
patient
return
previou
health
statu
follow
acut
febril
polyarthr
miscellan
longlast
rheumat
musculoskelet
disord
rmskd
report
consist
chronic
inflammatori
rheumat
cir
notabl
rheumatoid
arthriti
ra
post
chikinfect
stage
remain
challeng
treat
earli
use
diseasemodifi
antirheumat
drug
dmard
recommend
ra
chik
outbreak
reunion
island
chikrel
rsmkd
retrospect
categor
empir
use
dmard
start
methotrex
mtx
treat
cir
form
analyz
medic
file
patient
refer
rheumatologist
saint
deni
persist
rheumat
disord
month
proven
chik
infect
review
de
novo
postchik
rmskd
distinguish
exacerb
preexist
disord
among
patient
includ
suffer
de
novo
rsmkd
ra
account
spondylarthropathi
distal
undifferenti
polyarthr
seventytwo
patient
treat
mtx
reach
efficaci
case
versu
failur
case
sever
side
event
observ
group
efficaci
significantli
associ
earli
introduct
mtx
within
first
year
cir
progress
p
meet
strong
remind
effort
made
differ
field
drug
develop
potent
better
toler
compound
also
new
type
deliveri
system
may
lead
prevent
therapeut
use
effort
end
epidem
includ
multiprong
intervent
erad
paradigm
remain
well
aliv
indepth
viroimmunolog
studi
new
pharmacolog
gene
therapi
intervent
hand
hcv
infect
first
chronic
viral
diseas
abl
cure
issu
test
treat
hiv
remain
author
declar
compet
interest
author
particip
equal
articl
author
read
approv
final
manuscript
